Arti®cial neural networks (ANNs) are widely available and have been demonstrated to be superior to standard empirical methods of detecting, staging and monitoring prostate cancer. These algorithms have been statistically validated in diverse, well-characterized patient groups and are now being evaluated for clinical use worldwide. New variables based on demographic data, tissue and serum markers show promise for improving our ability to predict disease extent and outcome and may be integrated in future ANN models. This review focuses on recently developed neural networks for detecting, staging and monitoring prostate cancer.
Introduction
Arti®cial neural networks (ANNs) are non-linear, computational models for information processing with structures inspired by certain known properties of biological neural systems. They are composed of simple elements (neurons) operating in a collective fashion (network). As with biological nervous systems, the neural network function is determined largely by the connections between elements (weights). Training algorithms, thus forming non-linear patterns between predictor variables adjust the values of these connections. In cancer diagnosis, staging and monitoring predictive variables are often related in non-linear ways. Therefore a properly trained and validated neural network might give us a more accurate prediction than standard regression analyses or empiric decision systems.
Early detection of prostate cancer
The decision to undergo biopsy based upon digital rectal examination (DRE) and absolute cut-off values of total and free PSA is a dif®cult one for men and their physicians. In 1994, Snow et al 1 introduced a neural network that predicted biopsy results. This network was trained on more than 1500 cases and validated on additional 200 cases. The likelihood of ®nding prostate cancer on a biopsy was predicted with an accuracy of 87%. The ®rst widely utilized commercially available ANN in urologic oncology, the ProstAsure TM Index, was introduced two years later at the American Urological Association (AUA) convention in 1996 by Stamey and colleagues. 2 This ANN determines the relationship between age, total serum PSA, prostatic acid phosphatase (PAP), and the three isoenzymes of creatine kinase (CK) to estimate an`lndex zone' predicting the likelihood of having possible tumor. The ProstAsure TM index has found it's greatest application for the early detection of prostate cancer in men with total PSA levels `4.0 ng/ml. In a validation study, Stamey et al 3 measured the ProstAsure TM Index in 298 men (102 men with histologically con®rmed cancer, 88 men with no cancer but BPH, and 108 men with a normal DRE) with PSA values`4.0 ng/ml. The sensitivity and speci®city were 71% and 86%, respectively, for the detection of prostate cancer. In this group of men, the ANN was superior to DRE ®ndings and total PSA in predicting the presence or absence of prostate cancer.
Babaian et al 4 compared the ProstAsure TM Index to percent-free PSA for predicting the presence of prostate cancer on biopsy. When comparing the area under the receiver operating characteristic curve (ROC AUC) for these diagnostic tests in a group of 225 men with either biopsy-proven cancer (n 54), no cancer but BPH (n 77), or normal ®ndings (n 94), the ROC AUC was signi®cantly (P`0.01) better for the ProstAsure TM index (AUC, 0.95) than for percent free PSA alone (AUC 0.86). In recent studies comparing ProstAsure TM to percent-free PSA for detecting prostate cancer in men with a PSA level 4.0 ng/ml, Zhang et al 5 and Stamey et al 6 reported similar results. From these studies it can be concluded that the ProstAsure TM ANN is superior to the use of percent-free PSA alone for detecting cancer in men with a PSA`4.0 ng/ml.
The utility of percent-free PSA as an ANN input variable was recently studied by Tewari and associates, 7 who predicted the likelihood of a positive biopsy in men with a PSA between 4.0 and 20.0 ng/ml randomly taken from over 3000 men with prostate cancer or benign prostate disease. Patient age, total, and Percent-free PSA-serum levels were chosen as input variables to stratify men to one of three risk groups for a positive biopsy result (Figure 1 ). In the validation set of 1200 patients, the authors reported an AUC ROC of 0.68.
Snow and coworkers 8 presented a report of the use of an ANN to predict the likelihood of a positive biopsy based on data collected in the Tyrol Prostate Cancer Screening Program in Innsbruck, Austria and at The Johns Hopkins Hospital. This study evaluated over 1000 men who underwent TRUS-guided prostate biopsy obtained because of an elevated serum PSA level or abnormal DRE. An ANN was developed using input variables that included age, total PSA, percent-free PSA, race, and DRE ®ndings. The ANN predicted biopsy results better than any individual variable alone. The ANN was`trained' on 85% of the group and validated on the remaining 15%. Overall, 26% had a suspicious DRE, 30% were found to have cancer on biopsy and 67% had a total PSA greater than 4.0 ng/ml. Total PSA and percent free PSA were the best single predictors, whereas race, age and DRE status poorly predicted diagnosis in this primarily (97%) Caucasian population. The patients were strati®ed into a low-, intermediate-, and high-risk group for the likelihood of a positive biopsy. Better strati®cation in the high-risk and low-risk groups were achieved by the ANN than by total or percent-free PSA alone ( Figure 1 ). This ANN achieved an ROC AUC of 0.77 in the validation set.
Prediction of pathologic stage
In 1996, Douglas et al 9 applied 38 input variables to predict extraprostatic extension in 33 men randomly selected from 218 patient records. The network was trained and tested on 129 and 56 men respectively, and achieved a sensitivity of 94% and speci®city of 69%. Tewari and Narayan 10 subsequently performed a larger study assessing the usefulness of neural networks for pretreatment staging of prostate cancer patients. Several neural networks were constructed using data from 1200 patients who underwent pelvic lymphadenectomy and radical prostatectomy for clinically localized prostate cancer. Patients receiving preoperative hormonal or radiation treatment and those treated with cryotherapy were excluded. Race, age, digital rectal examination, transrectal ultrasound imaging, serum PSA, Gleason biopsy score, number of positive cores, bilaterality of cancer and perineural invasion were chosen as input variables to predict surgical margin status, seminal vesicle involvement, and/ or lymph node metastasis. In a testing set of 240 patients, the best network model achieved false negative values of 8%, 0%, and 2% for surgical margin status, seminal vesicle involvement, and lymph node metastasis, respectively.
Miller et al 11 developed an ANN based on a quantitative nuclear grade (QNG) derived from 227 prostate cancer patients to predict organ con®nement with an accuracy of 95%.
Partin et al 12 Ported the use of an ANN to predict pathological stage for a group of over 4300 men with newly diagnosed clinically localized prostate cancer. Total PSA, clinical stage, Gleason score, and age were chosen as input variables to compute a prostate staging index (PSI). After training the network on 420 men and cross-validating on another 420 men, a PSI-cutpoint of 0.0 was chosen to predict organ-con®nement in an independent test group of over 3400 patients. At this cutpoint, the sensitivity and speci®city of PSI were 73.3% and 61.5% respectively for predicting organ-con®ned status. The positive and negative predictive values were 63.4% and 71.8%, respectively. For each 0.5 increase in PSA, the odds of having organ-con®ned disease decreased by about one third (Figure 2 ). 11 . Total = all 3480 patients; PSI zone 1 `7 1.0 (n 543); PSI zone 2 7 1.0 to 7 0.1 (n 1372); PSI zone 3 0.0 to 0.9 (n 653); PSI zone 4 b 1.0 (n 912). White areas represent stages pT2NO, light gray areas stages pT3aN0, dark gray areas stages pT3bNO, and black areas stages pTxN1 (UICC 1997).
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Crawford and associates developed a predictive neural network using TNM stage, Gleason score and preoperative PSA values as input variables. 13 After the network was trained to predict lymph node involvement on a database taken from over 4000 patients, it was validated on a group of 227 patients from other institutions. This neural network correctly predicted the absence of lymph node involvement for a low-risk group of 25% of the 223 test patients. At less than 3%, the false negative rate was comparable to that obtained in multivariate regression nomograms.
A patient with newly diagnosed prostate cancer can now choose between a number of treatment options including brachytherapy, external beam radiation, retropubic and perineal prostatectomy. Gene therapy, although experimental now, might be an alternative treatment option in the near future. As the predictive accuracy of neural networks for prostate cancer staging continues to improve, pretreatment imaging studies and, when indicated, pelvic lymphadenectomy may assume less importance in counseling patients regarding their most appropriate treatment options.
Outcome prediction
In 1994, Snow et al 1 introduced a prostate cancer outcome prediction model, which uses a neural network. After a training phase on randomly chosen patients, testing the network on 52 men resulted in a 90% accuracy for the prediction of cancer recurrence. Douglas and coworkers reported an overall accuracy of 97% in predicting biochemical recurrence following prostatectomy. 9 Veltri and coworkers 14 used imaging information extracted from the prostate single biopsy cores of 45 men followed for 4.2 AE 2.0 y to develop an ANN with a predictive accuracy of 84%. Ragde et al 15 used a neural network to predict brachytherapy failure in 152 patients. Clinical stage, biopsy Gleason score, age, and pre-treatment PSA values were input variables. After training the ANN on 84% of the patients, a validation on the other 16% led to a 82% negative (no recurrence within 10 y) and a 76% positive predictive value at a sensitivity of 55% and speci®city of 90%.
Potter et al 16 followed 214 men at moderate and high risk of progression for a median of 9.5 y after radical retropubic prostatectomy. They developed three different neural networks on training sets of 136 patients and validated them on test sets 35 patients to predict biochemical recurrence. In this subset of men, accurate prediction of progression likelihood has historically been extremely dif®cult. Using various pathology features, age, nuclear morphometry and DNA-ploidy, or all of these variables combined, AUC ROCs of 0.713, 0.740 and 0.735 respectively for the random test sets were reported. All predictive models were superior to logistic regression in predicting progression.
In a feasibility study, Mattfeldt et al 17 compared different ANNs to logistic regression analysis for prediction of later recurrence after radical prostatectomy. In a set of 20 recurrent men found to have pT2N0 disease and 20 men without recurrence, matched for stage, age, preoperative PSA, and duration of follow-up, the best ANN con®guration achieved an accuracy of 90% for predicting recurrence, compared to 76% accuracy with logistic regression analysis.
A recent study on 284 patients integrating PSA as an input variable to predict biochemical failure following radical prostatectomy reported an AUC ROC of 0.814, thus pointing to an increased accuracy in ANN-based outcome prediction with the integration of pre-treatment PSA value. 18 The mean follow-up was only 31.8 months in this study, and longer follow-up periods are needed. These data will soon be available.
Approval, validation and applicability of ANNs for prostate cancer
Since the introduction of ANNs in prostate cancer diagnosis and outcome prediction by Snow et al in 1994, 1 numerous applications have been developed. However, any ANN of clinical relevance must be based on a well de®ned patient sample that is representative in terms of demographics, age, race, pathology, and treatment. It also has to be recognized that prostate cancer is now more often diagnosed in an earlier stage of disease and that therefore patient samples underlying an ANN ideally should include representative numbers of patients with pTlc disease and preoperative total PSA serum values below 4.0 ng/ml. Training of the model must be followed by testing with different cases not in the training set to assess model robustness.
All neural networks used for patient care are subject to regulation and approval by the Food and Drug Administration (FDA) 19 and currently only two ANNs have been allowed to market as information processing services: the ProstAsure TM Index 2 ± 6 produced by Horns Therapeutics, Inc. (Savannah, GA) and intended to de®ne the risk of prostate cancer at biopsy, and a brachytherapy outcome prediction model developed by Xaim, Inc. (Colorado Springs, CO). 15 Even after proper training and testing, an ANN's promising performance for a select group of patients from a single institution or geographic area does not assure utility in another group of patients. Differences in race, age, comorbidity and variations in retrieval and interpretation of clinical data may interfere with the predictive performance. Studies validated on different patient groups for prostate cancer diagnosis 5,6 and staging 13 have recently been published. These validation studies are needed to ensure ANN's general applicability in urology.
Future directions
Clinical trials investigating a new ProstAsure TM neural network which includes both race and percent-¯ee PSA are being initiated. Veltri and coworkers 14 continue to develop a concept combining patient speci®c risk factors, serum markers, biopsy pathology and ANN derived tissue morphology to predict stage and outcome. ANNs will play a signi®cant role in the assessment of clinical usefulness of newly developed markers for prostate cancer. Besides ANNs percent-free PSA, future variables which may prove useful as input variables for ANNs are serum markers such as complexed PSA, human kallikrein-2, prostate speci®c membrane antigen (PSMA)interleukin-8 mRNA, and insulin-like growth factor I. Promising new serum-4 and tissue-related prognostic factors are listed in Table 1 and Table 2 . Besides patient age, demographic variables like geographic data, race, and family history may prove useful as input variables. In ANN-based outcome prediction, the integration of pretreatment PSA-levels is now available for longer follow-up periods and will certainly improve predictive accuracy.
As with former ANNs, optimizing the predictive accuracy by determining which factors to use as input variables and how to weigh and combine them was often time-consuming. New computing techniques (genetically engineered neural networks) that develop a network's optimal con®guration on the data presented are now commercially available and will contribute to determine the role of promising new markers. 16 
Conclusions
Arti®cial neural networks (ANNs) are often superior to empirical statistical methods or models based on univariate regression alone 20 and demonstrate superior predictive accuracy to multivariate regression analysis when variables are related in a non-linear fashion. 21 ANNs have recently been approved by the FDA for prostate cancer diagnosis and outcome prediction in brachytherapy. 15 Some ANNs have also been validated on well-de®ned patient groups from other clinical settings, thus proving their general applicability. Neural networks will play a major or role in determining the value of new serum and tissue markers in prostate cancer diagnosis and clinical decision making. 16 
